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Canada has been home to a longstanding public health crisis related to opioids, including an extensive mortality
and morbidity toll in the face of substantive intervention gaps. Recently (2019), two extensive reports from
preeminent federal authorities – the Chief Public Health Officer and the Mental Health Commission of Canada –
have been tabled with detailed, core focus on the phenomenon of ‘stigma’ and its impacts on substance/opioid
use and harms. The reports present extensive descriptions of the nature and effects, as well as a multitude of
prescriptions for remedial measures and actions to “stop the cycle of stigma”. Closer reading of the documents,
however, suggests substantial conceptual and empirical limitations in the characterization of the – multi-faceted
and challenging – nature and workings of ‘stigma’ as a socio-political, structural or individual process or force,
specifically as it applies to and negatively affects substance use and related outcomes, primarily the wellbeing of
substance users. Concretely, it is unclear how the remedial actions proposed will materially alleviate stigma process
and impacts, especially given apparent gaps in the issues examined, including essential strategies – for example,
reform of drug user criminalization as a fundamental element and driver of structural stigma - for action that
directly relate to the jurisdictions and privileged mandates of the report sources themselves as health and policy
leaders. The commentary provides some concrete while subjective notes and observations on the dynamics of
stigma as applies to and framed for substance/opioid use, as well as strategies and measures necessary to both
tangibly address the material health and wellbeing of substance users, and related forces of stigma, in the distinct
context of the opioid crisis in Canada.
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Canada has been entrenched in an unprecedented public
health crisis related to opioids for far more than a dec-
ade [1]. This crisis has taken an estimated 20–25,000
(mostly young or middle-aged) lives through opioid poi-
soning (overdose) fatalities over the most recent past 10
years, with > 4600 such deaths alone in 2018 [2, 3]. Even© The Author(s). 2020 Open Access This artic
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related mortality on the general population’s life expect-
ancy has been ascertained [4]. For years now, there have
been fundamentally urgent and persistent calls (and cor-
respondingly numerous promising statements) for ex-
panded, better and overall more effective responses to
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two prominent, federal-level reports, 1) The Chief Public
Health Officer’s (CPHO) Report on the ‘State of Public
Health in Canada’ [5], 2) the Mental Health Commission of
Canada’s (MHCC) Report on ‘Stigma and the Opioid Crisis’
[6] were tabled and widely disseminated. Both these elabor-
ate reports centrally focus on the role of ‘stigma’ for chronic
disease and public health, and specifically ‘substance use’
and the ‘opioid crisis’ (the MHCC report with such exclu-
sive focus, the CPHO report within a broader focus on
stigma and public health). ‘Stigma’, at its foundations, is a
sociological concept, crucially furthered by the Canadian-
born sociologist Erving Goffman [7, 8]. Essentially, it indi-
cates the ascription of negative attributes or assumptions
(or ‘stereotypes’ or ‘mark of disgrace’) on a person because
of certain properties or behaviours outside their control,
and consequential loss in social status, opportunity, and
care or support (including possible ‘discrimination’) [9].
Luoma provides some essential conceptual and prac-
tical characteristics of stigma. Stigma is produced and
reproduced in many ways, including common ‘cultural
practices’ of everyday life, and highly resistant to change.
It can be helpful to distinguish between ‘organizational’
or structural level, and individual-level processes of
stigma, both of which include (structural or individual,
respectively) ‘prejudice’ and ‘discrimination’ as ways of
enactment of stigma. For example, organizational/struc-
tural stigma, through related power processes, involves
(intentional or un-intentional) policies or organizational
rules, restrictions or opportunity barriers towards stig-
matized group; whereas individual-level stigma can be
divided into public (e.g., the individual reactions or judg-
ments) about a stigmatized group (e.g., ‘addicts’) as well
as ‘self-stigma’ (e.g., the internalization of negative self-
value and status, and consequential self-preclusion from
key opportunities (e.g., treatment) or negative outcomes
experienced by the stigmatized individual themselves. A
large variety of different strategies and approaches to reduce
stigma have been identified and tried, with however limited
demonstrated effects on reducing stigma [10].
‘Stigma’ has been given distinct (while limited, e.g.,
when compared to mental health) attention in the psy-
choactive substance use realm, in part also related to the
conflicting underlying social concepts or explanations
(e.g., crime versus moral failure versus disease models)
of ‘addiction’, and consequential implications for the so-
cial identities, status and interventions geared at the user
[9]. Luomo notes that research on stigma in the addic-
tion realm is in its “infancy”, and that even less is known
on “how to reduce stigma in this area.” [10]
Two pre-eminent ‘anti-stigma’ manifests
Both above-mentioned reports ascribe fundamental and
sweeping cause-effect agency, as well as necessaryremedial prescriptions to the phenomenon of ‘stigma’ as
applied to the current public health crisis of substance/
opioid use in Canada. For example, the CPHO’s report
lays out in elaborate detail [5]; pp.23–56] how ‘stigma’
creates a fundamental “us versus them” between sub-
stance users and society, resulting not only in “signifi-
cant economic costs, barriers to housing, employment,
health care, productivity loss”, functions as the root of
“discrimination”, wrongfully blames substance users for
“poor willpower”, and projects them to be “dangerous
and reckless” and implies them to be not suffering from
“real illness”. Beyond, stigma is listed as a driving factor
of decreased service use, concealment of substance use,
and health-harming coping behaviours (e.g., isolation,
needle sharing), poorer health and quality-of-life (QOL),
limited treatment uptake and poorer outcomes for sub-
stance users. Based on remedies prescribed for the stigma
“cycle [to be] effectively stopped” and for “resisting the im-
pacts of stigma” it is emphasized that required action need
to occur on many (e.g., individual, institutional, popula-
tion) levels, yet concretely by changing “biased and out-
dated language”, “strengthening resilience” (e.g., through
education), and devising “cultural competence” interven-
tions for health care providers towards the development
of “awareness, knowledge and attitudes”. All the while it is
then categorically acknowledged in the report that “it is
difficult to know ‘what works’, in what context, to address
stigma and discrimination” (p.53).
Similarly, the MHCC’s report [6] – including a related
review paper from one of the authors as integrated elem-
entary content material [11] - purports “broad agree-
ment […that…] stigma surrounding opioid use is both
significant and consequential” and has acted “as a barrier
to reframe the opioid crisis as a public health issue”,
concretely as it “affects how we conceptualize, frame and
prioritize [the opioid] crisis.” Stigma is furthermore
stated to lead to “hiding and creates barriers to help-
seeking, [… and that it] contributes to ongoing system
mistrust and avoidance of services […and…] results in
poorer quality care and response”. For principal remed-
ies, these campaign documents then – specifically also
as actions geared towards “health leaders” - prescribe
“comprehensive stigma reduction and intervention strat-
egies for frontline providers”, “address[ing] the ethical
dilemmas experienced by … front-line providers regard-
ing high-recidivism clients and the emergency-relief
measures (e.g., Narcan) that may increase risk-
behaviors”; and “increas[ing] the use of non-stigmatising
language and establish[ing] best practice guidelines for
opioid-related terminology and language”; ensuring
“stigma-informed … prevention and policies efforts”; and
removal of “organizational and policy-related barriers …
to a full range of care interventions and services”. Yet
here also, it is then acknowledged that "the evidence
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area is thin, and first requires a “more robust body of
evidence”. In related media release-statements, the
CPHO publicly called on “health leaders to tackle stigma
[and] that we are all responsible for stopping it” [5], and
the MHCC’s CEO declares that “naming stigma as a
public health crisis is brave, bold and necessary.” [12]
One could be left with the distinct impressions, based on
the above documents and statements, that the opioid crisis
and its grave health and social toll in Canada are primarily
a product of forces of ‘stigma’, and that implementing the
suggested remedies will reliably guide and bring about
much awaited, tangible improvement and solutions. While
‘stigma’ is a certainly present phenomenon and social dy-
namic in the substance use realm, and adversely affects sub-
stance users’ lives, behaviors and care in a multitude of
ways, the above observations and remedies appear to be
problematically narrow if not simplistic at key ends, while
selective and featuring essential gaps in key elements and
elaborations – especially also when considering their origin-
ating sources. These impressions sit uneasily, and warrant
some basic while subjective consideration and comments as
per the following brief summaries of main illustrative
examples:
1) An (if not the) essential root driver and
determinant of ‘stigmatization’, or the enactment of
a fundamentally divisive ‘us versus them’ disposition
for psychoactive substance users – for example,
opioid users in the specific context of the opioid
crisis, but beyond involving other illicit substances
in other contexts -- is the fact that such use is
categorically defined as a (criminally) illegal. This is
so the case in Canada specifically per definition of
the Controlled Drugs and Substance Act (CDSA).
Arguably, there is no more powerful and impactful
social tool to create, and project stigma on a
structural level, and its direct and indirect adverse
consequences, than through criminalizing a specific
behavior and the people such criminalization
identifies and targets [13]. The criminal law, by
definition, non-negotiably defines and enshrines
most fundamental and shared social norms and
values, and identifies actions and behaviors that
violate and harm the social body of common rules
which are then prescribed punishment as the state’s
most powerful form of power [14]. The criminal
law, therefore constitutes the authoritative, state-
sanctioned basis and seal of stigma in the context of
a law-based society: for primary examples ‘murder’,
‘treason’ or ‘assault’ carry irrevocable, heavy, official
‘stigma’ for the law-breaking act, and those who
commit it. Moreover, the criminal law, or the
process of crminalization, defines socially harmfuland shunned actions, both by official and formal
definition and its every-day enactment (e.g.,
enforcement); additionally, criminalization serves as
the ultimately legitimate reference or justification
for certain behaviors – or their ‘actors’ – to be
differentiated, excluded, or penalized from many
realms of life. Beyond, there is extensive scientific
evidence on how ‘criminalization’ adversely affects
substance use-related risks, harms and help seeking
or service access [15–17]. Yet, nowhere do either
report centrally name this quintessential link, or
provide explicit recommendations that the
‘criminalization’ of drug use as a root driver of
‘stigma’ consequences ought to be materially cor-
rected for the “cycle of stigma” to be slowed or
stopped. This is particularly surprising since both
reports come from leading federal government
(CPHO) or arms’ length (MHCC) entities located at
the very jurisdictional level of the CDSA as federal
law in Canada. Both entities would be in a preemi-
nent position to recognize, and emphasize for the
explicit criminalization of substance (opioid) use as
a primary, fundamental foundation of stigma that
requires revision in order for the desired ‘stigma re-
duction’ to occur.
2) Similarly, there are other concrete, major
intervention and policy actions – or gaps, rather –
towards opioid-related public health measures along
the lines of barriers and obstacles mentioned in
theory that, for long, have been resisted by the very
anti-stigma campaign protagonists. Tangibly, federal
government authorities, for considerable time, have
refused to formally call a ‘public health emergency’
(under the Emergencies Act in Canada) in response to
the opioid crisis that would have allowed
considerably more flexible and substantive measures
to address and reduce related health risks and
adverse outcomes, including the massive overdose
mortality toll [18, 19]. Related, federal authorities
have long resisted the implementation of broad-
based, systematic provisions and measures for com-
prehensive ‘safer opioid’ distribution programming
towards better protecting the numerous ‘at-risk’ opi-
oid users from increasing exposure to highly toxic/
potent, illicit opioid supply and elevated risk for over-
dose and death [20–22]. Both types of measures re-
flect and mimic standard interventions applied and
enacted elsewhere (e.g., for vaccinations for influenza,
or acutely extensive transmission control measures
COVID-19 etc. [23]). On this basis, seemingly,
preeminent health leaders emphasizing the
exceptional burden from and need to “end the stigma
cycle” themselves appear to be hindered or hesitant
in their own efforts by ‘stigma-related policy barriers’
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termined, concrete action.
3) The respective CPHO and MHCC reports appear
to present a questionably one-directional or
simplistic perspective on the mechanics and nature
of ‘stigma’. While the reports’ analyses suggest
multiple ‘pathways’ or ‘layers’ of stigma, they
essentially appear to suggest that ‘stigma’ is an
exclusively negative force in functioning and
outcomes, and brings on extensive harm in
whatever it touches or affects; therefore, any
available measures ought to be deployed for it to be
‘purged’ for its major, consequential harms to be
reduced in desirable ways for general benefit. But
the dynamics and workings of ‘stigma’, if considered
more fulsomely, are much more complex, or multi-
dimensional. For example, while surely there should
not be genuine intent to negatively label, or
categorically stereotype, drug users as ‘bad persons’,
there are many behaviors – in the social realities of
daily life, health, or substance use – that are widely
recognized and agreed as factually unhealthy and
undesirable, and therefore feature legitimate reason
(e.g., for the benefit of interventions) to be
negatively labelled. For example, ‘drinking and
driving’, smoking in front of children, sharing
injection paraphernalia, or stealing are generally
agreed-upon risky or harmful behaviors which are
– for education or prevention messaging or
deterrence purposes – negatively labelled and so
conveyed for arguably good reason [24, 25]. It
cannot be in anyone’s (and especially not prominent
health leaders’) real interest to suggest correction of
these behaviors to positive, or even neutral status or
messaging in the interest of all-encomassing ‘stigma
reduction’. Rather, the real, while presumably more
complex challenge for a meaningful addressing of
stigma appears to be, as far as possible, to dis-
associate concrete, while undesirable or shunned
behaviors and their negative labels from the general
identity of those individuals or human beings who
engage in or are associated with them, or least bet-
ter consider and contextualize their real-life con-
texts, but not have their social or health or other
existential opportunities categorically labelled or
negatively burdened by them [10, 26]. This separ-
ation of value attributions is not an easy task, also
given that negative behaviors do not exist without
people associated with them, and one that will likely
never be perfectly possible; however, to imply or in-
voke a functioning social world in which everything
and anything will be free of negative labels – i.e.,
without any negative association or labels – is nei-
ther meaningfully possible nor workable.4) Specifically in the realm of the opioid crisis and its
distinct evolution, there have been other, powerful
forces of social ‘labelling’ or associations at work
that may be (perhaps somewhat clumsily) referred
to as ‘false’ or ‘reverse stigma’ (i.e., suggesting
misguided positive signals or properties on
behaviors where the opposite, or at least active
prudence or caution would have been warranted);
these can be assumed to have led to at least as
much, but likely far more, opioid-harms in the
population as the genuine (adverse) ‘stigma’ drivers
and effects laid out in the reports. As a key example,
an essential causal driver of the opioid crisis, specif-
ically as it unfolded in North America, has included
the widespread, excessive medical availability, pre-
scription and usage of potent opioid medications
starting in the early 2000s. The vast increases in
general population-wide opioid use, initially under
the premise of improved population-wide pain care
and featuring new - supposedly effective and side
effect-free - opioid medications (e.g., oxycodone)
aggressively promoted by pharmaceutical compan-
ies and facilitated by skewed prescription guidelines,
insufficient regulation and prescriber practices alike,
pushed large sub-populations into hazardous trajec-
tories of opioid use, with many resulting in misuse,
dependence or overdose deaths [27–29]. Later opi-
oid formulations – incorrectly – were claimed to be
‘abuse-deterrent’ or ‘tamper-resistant’, and therefore
safe from harm [30, 31]. All this related to
government-licensed and -approved drugs, and
occurred under the knowing eye of government
monitoring and regulatory control. For (too) long,
key government and regulatory authorities provided
no relevant policy responses, and then did ‘too little
too late’, to stop the detrimental dynamics of the
opioid crisis and its massive population health
harms unfolding in slow-motion [28]. As much as
negative ‘stigma’ may push some opioid users into
riskier behaviors or contribute to help or service ac-
cess barriers and inferior care quality, as much did
misleadingly, or simply false systemic positive social
messages, images and pervasive assumptions about
opioid medications and their alleged benefits, and
related harmful (e.g., over-prescribing) practices en-
dorsed or tolerated by key authorities contribute to
the present opioid public health crisis. (Notably,
one of the reports considered points out that users
of ‘prescription opioids’ “also” experienced negative
stigmatization, making users feel “addicted … as
much as a heroin addict” – implying a needed dif-
ferentiation in stigma attribution between users of
'medical' and 'non-medical' drugs) ([6], p.44). These
above factors ought to be taken into account
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social process influencing behaviors and adverse
outcomes, whereas these are complemented by
other social processes leading to and contributing
to the same problem's formation and consequences.
5) There is a sizeable, recent body of scientific literature
– e.g., specifically including systematic reviews from
the past decade – devoted to stigma, substance use
and related interventions. Surprisingly, little of these
evidence-based insights appear to be considered in
comprehensive depth in either of the two documents.
For example, while respective reviews find ample evi-
dence for a common presence of negative attitudes
and beliefs towards substance users among health
professionals or policy representatives, and
correspondingly ample accounts of such experiences
and consequences among substance users themselves,
other key elements of empirical knowledge on or
understanding of ‘stigma’, and especially effective
counter-actions appear to be much more restricted
[32–34]. Concretely, there is a lack of essential con-
struct, measurement and definitional clarity and
consistency, and a dearth of rigorous (e.g., longitu-
dinal) studies and other research on stigma [32, 35];
there overall are few consistent findings on the rela-
tionship between stigma and substance use, and few
studies have evaluated actual consequences of subject-
ive ‘stigma’ impressions [36]; and evidence on effective
stigma-reducing interventions is considered limited
[37]. Crapanzano et al. (2014) report the notable find-
ing in their (medical student) study sample that these
believed that stigma beliefs among health care profes-
sionals were indeed common, but that their own be-
liefs and care practices would not be influenced by
these [38].
Conclusions
There appears to be good reason for some sensible re-
flection or restraint to be applied on the above stigma-
fighting campaign and action front, specifically as gener-
ously projected on the ‘opioid crisis’ in Canada. There is
little doubt that ample stigmatizing forces and experi-
ences exist and crucially work against the health and
wellbeing of substance users in many ways, and should
be tackled and alleviated. To which extent this can be
most effectively achieved mostly by ‘language adjust-
ments’, ‘resilience strengthening’ or similar efforts sug-
gested, everyone may consider and guess for themselves
– also since current scientific knowledge does not pro-
vide much conceptual clarity or substantive evidence
what such efforts tangible mean or can accomplish in
material reality. The dynamics and effects of stigma for
substance use, and both meaningful and realistic ways
towards addressing and working to resolve these,however, can be assumed to be much more complex and
challenging than what the above-cited two documents
and their - rather narrow, if not simplistic - accounts
suggest. They may be so described, since they present
only limited insights on the (e.g., structural, social and
individual) causes or drivers of stigma for substance use,
and possible promising and effective remedies for mater-
ial and sustained change in the lives of those concerned
(i.e., substance users). These factors require, and deserve,
deeper and better examination and analysis for realistic
contributions and improvements for the important
stigma-related causes and issues at hand – especially
from the leading and privileged authorities from which
have put forward these reports. First and foremost, the
quintessential causal role of the criminalization of illicit
substance use (and thereby its users) for the pervasive pro-
duction of structural stigma needs to feature prominent
recognition, and related calls for change in such a cam-
paign if sincerely committed to effective and material
stigma reduction.
There appear, however, a couple of other latent risks or
adverse effects associated with this kind of ‘en passant’-
kind of ‘anti-stigma’ presentation and campaigning that
avoids to name core causes and elements. One is that it
can be dangerously seductive as a self-righteous, or
serving platform on which now ‘stigma’ is staged as a con-
venient, general or principal ‘scapegoat’ for the opioid cri-
sis, and its ongoing massive and persistent harms. Calling
out, rejecting and fighting ‘stigma’ as a socially shared vil-
lainous force – akin, for example, to N. Christie’s ‘suitable
enemy’ concept for illicit drugs [39] – is somewhat similar
to promoting ‘motherhood and apple-pie’ (or supporting
justice, equality, and peace for all), while rather limited in
applied value or impact if mainly remaining at rhetorical
or symbolic levels, and not realistically translated into ne-
cessary material action or change at the causal founda-
tions. The other is that such social campaigns may (too
easily) serve as a distraction from those tangible or struc-
tural actions or measures urgently required to improve
and protect the existential real-life conditions, and elem-
entary health and wellbeing (including basic, daily survival
through effective, comprehensive overdose prevention ser-
vices) of the many at-risk opioid (or all substance) users.
The current, long-lasting fight against the opioid public
health crisis will not be won by campaigns against stigma
in itself. Rather, fundamental drug law and policy reform,
i.e. purging the intent criminalization (and related material
stigmatization) of drug use/possession as a ‘criminal act’,
and consequentially defining ‘the user’ as a criminal being
with all adverse consequences – including fundamentally
negative stigma – that entails is a (the) foremost action
priority for this end [40]. Much of this, if materially
enacted, will provide and bring fundamentally ‘de-stigma-
tizing’ effects for substance users in many crucial (direct
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laid out in the report documents mentioned, and thus
form quintessential gaps towards substantive and effective
anti-stigma efforts in this realm.
Concretely, after > 25,000 opioid-related deaths in
merely a decade, Canada yet in 2020 lacks essential ele-
ments of a comprehensive, consistent and committed
‘public health emergency’ strategy, and essential public
health interventions, including reliable, national ‘safer
opioid distribution’ provisions, for at-risk opioid users. It
is when these urgent, material remedy needs and action
gaps are effectively addressed by the health and policy
leaders in charge, we should devote resources to an im-
proved, in-depth understanding and effective addressing
of what may be the remaining elements of stigma in the
real of substance use, and the people who use them.
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